Senolytic compounds reduce epigenetic age of blood samples in vitro

Senolytic drugs raise the expectation that they can specifically eliminate a subset of senescent cells in a given tissue. In this study, we have exemplarily analyzed if a 3-day treatment of human blood samples in vitro would reduce age-associated biomarkers, with a particular focus on epigenetic age-predictions. Of eight tested compounds, JQ1, RG7112, nutlin-3a, and AMG232 reduced epigenetic age, indicating that this approach may be useful in drug screening for senolytic compounds.